510 related articles for article (PubMed ID: 26901026)
1. Reassessment and Follow-Up Results of BI-RADS Category 3 Lesions Detected on Screening Breast Ultrasound.
Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH
AJR Am J Roentgenol; 2016 Mar; 206(3):666-72. PubMed ID: 26901026
[TBL] [Abstract][Full Text] [Related]
2. Probably benign lesions at screening breast US in a population with elevated risk: prevalence and rate of malignancy in the ACRIN 6666 trial.
Barr RG; Zhang Z; Cormack JB; Mendelson EB; Berg WA
Radiology; 2013 Dec; 269(3):701-12. PubMed ID: 23962417
[TBL] [Abstract][Full Text] [Related]
3. Assessment of BI-RADS category 4 lesions detected with screening mammography and screening US: utility of MR imaging.
Strobel K; Schrading S; Hansen NL; Barabasch A; Kuhl CK
Radiology; 2015 Feb; 274(2):343-51. PubMed ID: 25271857
[TBL] [Abstract][Full Text] [Related]
4. Growing BI-RADS category 3 lesions on follow-up breast ultrasound: malignancy rates and worrisome features.
Ha SM; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH
Br J Radiol; 2018 Jul; 91(1087):20170787. PubMed ID: 29658793
[TBL] [Abstract][Full Text] [Related]
5. Revisiting the mammographic follow-up of BI-RADS category 3 lesions.
Varas X; Leborgne JH; Leborgne F; Mezzera J; Jaumandreu S; Leborgne F
AJR Am J Roentgenol; 2002 Sep; 179(3):691-5. PubMed ID: 12185047
[TBL] [Abstract][Full Text] [Related]
6. Surveillance of probably benign (BI-RADS 3) lesions in mammography: what is the right follow-up protocol?
Buch KA; Qureshi MM; Carpentier B; Cunningham DA; Stone M; Jaffe C; Quinn M; Gonzalez C; LaVoye J; Hines N; Bloch BN
Breast J; 2015; 21(2):168-74. PubMed ID: 25669425
[TBL] [Abstract][Full Text] [Related]
7. Screening US in patients with mammographically dense breasts: initial experience with Connecticut Public Act 09-41.
Hooley RJ; Greenberg KL; Stackhouse RM; Geisel JL; Butler RS; Philpotts LE
Radiology; 2012 Oct; 265(1):59-69. PubMed ID: 22723501
[TBL] [Abstract][Full Text] [Related]
8. [Performance of users in tropical areas with the BI-RADS classification of breast lesions for predicting malignancy].
Gonsu Kamga JE; Moifo B; Sando Z; Guegang Goudjou E; Nko'o Amvene S; Gonsu Fotsin J
Med Sante Trop; 2013; 23(4):439-44. PubMed ID: 24334372
[TBL] [Abstract][Full Text] [Related]
9. Accuracy of classification of breast ultrasound findings based on criteria used for BI-RADS.
Heinig J; Witteler R; Schmitz R; Kiesel L; Steinhard J
Ultrasound Obstet Gynecol; 2008 Sep; 32(4):573-8. PubMed ID: 18421795
[TBL] [Abstract][Full Text] [Related]
10. Retroareolar masses and intraductal abnormalities detected on screening ultrasound: can biopsy be avoided?
Guo Y; Raghu M; Durand M; Hooley R
Br J Radiol; 2018 Oct; 91(1090):20170816. PubMed ID: 29338316
[TBL] [Abstract][Full Text] [Related]
11. Use of BI-RADS 3-probably benign category in the American College of Radiology Imaging Network Digital Mammographic Imaging Screening Trial.
Baum JK; Hanna LG; Acharyya S; Mahoney MC; Conant EF; Bassett LW; Pisano ED
Radiology; 2011 Jul; 260(1):61-7. PubMed ID: 21502382
[TBL] [Abstract][Full Text] [Related]
12. Cancer Yield and Patterns of Follow-up for BI-RADS Category 3 after Screening Mammography Recall in the National Mammography Database.
Berg WA; Berg JM; Sickles EA; Burnside ES; Zuley ML; Rosenberg RD; Lee CS
Radiology; 2020 Jul; 296(1):32-41. PubMed ID: 32427557
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of the results after using of the BI-RADS categories in 1,777 clinical mammograms].
Hauth EA; Khan K; Wolfgarten B; Betzler A; Kimmig R; Forsting M
Radiologe; 2008 Mar; 48(3):281-8. PubMed ID: 17265008
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of unconventional utilization of BI-RADS category 3 assessment at opportunistic screening.
Altas H; Tureli D; Cengic I; Kucukkaya F; Aribal E; Kaya H
Acta Radiol; 2016 Nov; 57(11):1304-1309. PubMed ID: 26019241
[TBL] [Abstract][Full Text] [Related]
15. Characteristics, Malignancy Rate, and Follow-up of BI-RADS Category 3 Lesions Identified at Breast MR Imaging: Implications for MR Image Interpretation and Management.
Chikarmane SA; Birdwell RL; Poole PS; Sippo DA; Giess CS
Radiology; 2016 Sep; 280(3):707-15. PubMed ID: 27089027
[TBL] [Abstract][Full Text] [Related]
16. Patient compliance and diagnostic yield of 18-month unilateral follow-up in surveillance of probably benign mammographic lesions.
Chung CS; Giess CS; Gombos EC; Frost EP; Yeh ED; Raza S; Birdwell RL
AJR Am J Roentgenol; 2014 Apr; 202(4):922-7. PubMed ID: 24660725
[TBL] [Abstract][Full Text] [Related]
17. [Ultrasound follow-up of palpable solid, probably benign breast lesions (BI-RADS category III)].
Graf O; Helbich TH; Fuchsjäger MH; Hopf G; Morgun M; Graf C; Mallek R
Rofo; 2004 Sep; 176(9):1251-6. PubMed ID: 15346259
[TBL] [Abstract][Full Text] [Related]
18. Computer-aided classification of BI-RADS category 3 breast lesions.
Buchbinder SS; Leichter IS; Lederman RB; Novak B; Bamberger PN; Sklair-Levy M; Yarmish G; Fields SI
Radiology; 2004 Mar; 230(3):820-3. PubMed ID: 14739315
[TBL] [Abstract][Full Text] [Related]
19. Utility of BI-RADS Assessment Category 4 Subdivisions for Screening Breast MRI.
Strigel RM; Burnside ES; Elezaby M; Fowler AM; Kelcz F; Salkowski LR; DeMartini WB
AJR Am J Roentgenol; 2017 Jun; 208(6):1392-1399. PubMed ID: 28792802
[TBL] [Abstract][Full Text] [Related]
20. Outcome of breast lesions detected at screening ultrasonography.
Kim SJ; Chang JM; Cho N; Chung SY; Han W; Moon WK
Eur J Radiol; 2012 Nov; 81(11):3229-33. PubMed ID: 22591758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
